Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV Melanoma.
Teresa AmaralOlivia SeeberEdgar MersiStephanie SanchezIoannis ThomasAndreas MeiwesAndrea ForschnerUlrike LeiterThomas EigentlerUlrike KeimClaus GarbePublished in: Cancers (2020)
Melanoma patients with primary resistance to immunotherapy have a dismal prognosis. Response at the first tumor assessment after starting immunotherapy is a stronger prognostic factor for the further course of the disease than pretreatment risk factors.